World First In 3D Printing Gives A Personal Touch To Keep The Blood Flowing
4 June 2020 Researchers from CSIRO, Australia’s national science agency, have made it possible to 3D print tailor-made stents, a critical biomedical device used to treat narrow or blocked arteries. The breakthrough, made in partnership with Wollongong-based Medical…
Read More$66 million for coronavirus-related research
2 June 2020 The Morrison Government is investing $66 million into finding a vaccine and treatments for COVID-19, as well as better preparing for future pandemics. This research will enable Australia’s world-class researchers to contribute to global efforts…
Read MoreAustralian Government invests in new medicines for COVID-19
2 June 2020 The Australian Government will invest $3M in Walter and Eliza Hall Institute research programs that are developing new classes of medicines for COVID-19. The funding from the Medical Research Future Fund (MRFF) will support…
Read MoreAtmo Biosciences raises $2.5m in seed financing
2 June 2020 Melbourne and Sydney, Australia – Atmo Biosciences, a digital health business which provides objective real-time insights into gut health and microbiome function, has raised a further A$2.5 million in an oversubscribed funding round, supplementing an…
Read MoreDimerix Drug in WHO COVID-19 Trial
4 June 2020 Global platform trial taps Australian drug for major global COVID-19 treatment study As the world mobilises to bring to bear the full scientific resources it can to fight the COVID-19 pandemic, an Australian biotech…
Read MoreAbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
1 June 2020 AbbVie, a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, today announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 is…
Read MoreCertara Broadens and Increases Regulatory Strength with Two Executive Hires
21 May 2020 Certara®, the global leader in model-informed drug development and regulatory science announced the appointments of Terrance (Terry) Ocheltree, Ph.D., R.Ph. as vice president of regulatory strategy and chemistry, manufacturing and controls (CMC) and Lynne Georgopoulos,…
Read MoreHuman insulin enhanced with cone snail ‘blue print’
2 June 2020 Diabetes treatments could be improved following the development of a dramatically modified form of human insulin, called ‘Mini-Ins’, that successfully mimics the ultra-fast-acting properties of cone snail venom insulin. Mini-Ins has demonstrated significant promise…
Read MoreNoxopharm: ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
1 June 2020 Highlights: NOX66 (Veyonda®) clinical data released to world-wide audience Anti-cancer responses (tumor size and pain responses) observed in approximately two-thirds of men with end-stage prostate cancer Abscopal responses in approximately one-quarter of men with end-stage…
Read MoreImmutep Reports First Results from INSIGHT-004 Study
1 June 2020 First data from this collaboration study with Merck KGaA, Darmstadt, Germany, and Pfizer Inc and sponsor, IKF, presented at ASCO Encouraging early activity signals in a variety of cancer indications Overall, 33% of patients showed…
Read MoreImmutep Announces Improving Data from Phase II TACTI-002 Study
1 June 2020 First complete response reported in 2nd line head and neck squamous cell carcinoma (HNSCC) Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR) Progression free survival (PFS) continues to improve in…
Read MoreImmutep Receives A$3.6 Million R&D Tax Incentive from French Government
29 May 2020 Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €2,173,454 (~ A$3,630,000) research and development (R&D) tax incentive payment in cash…
Read More
